Abstract
Background The multikinase inhibitors (MKIs) sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan. How sequent......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
